The University of Southampton
University of Southampton Institutional Repository

Fluarix quadrivalent vaccine for influenza

Fluarix quadrivalent vaccine for influenza
Fluarix quadrivalent vaccine for influenza
Influenza A and B infections cause significant morbidity and mortality. Over the past 30 years, two main influenza B strains have been circulating globally. The trivalent influenza vaccine used in the last 25 years contains one B strain, with approximately 31% of B strain disease coverage over the last 10 years. Fluarix quadrivalent vaccine, containing two A and two B strains, combines the components of two existing trivalent vaccines to prevent this mismatch. This review gives an overview of the published data about Fluarix quadrivalent vaccines, showing an immunogenicity and safety profile of the vaccine comparable with the two licensed trivalent vaccines containing the same strains, but with no evidence for efficacy in the literature. Future vaccines aim for a universal influenza vaccine that will give a long-lasting protection against all influenza strains

1476-0584
1055-1063
de Graaf, Hans
447e78ed-346f-45bb-9238-fce2118d5559
Faust, S.N.
f97df780-9f9b-418e-b349-7adf63e150c1
de Graaf, Hans
447e78ed-346f-45bb-9238-fce2118d5559
Faust, S.N.
f97df780-9f9b-418e-b349-7adf63e150c1

de Graaf, Hans and Faust, S.N. (2015) Fluarix quadrivalent vaccine for influenza. Expert Review of Vaccines, 14 (8), 1055-1063. (doi:10.1586/14760584.2015.1057573).

Record type: Article

Abstract

Influenza A and B infections cause significant morbidity and mortality. Over the past 30 years, two main influenza B strains have been circulating globally. The trivalent influenza vaccine used in the last 25 years contains one B strain, with approximately 31% of B strain disease coverage over the last 10 years. Fluarix quadrivalent vaccine, containing two A and two B strains, combines the components of two existing trivalent vaccines to prevent this mismatch. This review gives an overview of the published data about Fluarix quadrivalent vaccines, showing an immunogenicity and safety profile of the vaccine comparable with the two licensed trivalent vaccines containing the same strains, but with no evidence for efficacy in the literature. Future vaccines aim for a universal influenza vaccine that will give a long-lasting protection against all influenza strains

Full text not available from this repository.

More information

e-pub ahead of print date: 22 June 2015
Published date: August 2015
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 378337
URI: http://eprints.soton.ac.uk/id/eprint/378337
ISSN: 1476-0584
PURE UUID: aeb79167-0716-4df1-a620-efbd679958ff
ORCID for S.N. Faust: ORCID iD orcid.org/0000-0003-3410-7642

Catalogue record

Date deposited: 02 Jul 2015 08:40
Last modified: 18 Feb 2021 17:07

Export record

Altmetrics

Contributors

Author: Hans de Graaf
Author: S.N. Faust ORCID iD

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×